Loading stock…

AtriCure, Inc. (ATRC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

AtriCure, Inc.

ATRCMarket cap $2.71BPrice $53.3

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

AtriCure makes devices that treat atrial fibrillation and reduce stroke risk by closing off a tiny heart pouch where 90% of AFib-related blood clots form. Surgeons worldwide rely on its tools during cardiac procedures to fix irregular heartbeats permanently.

In Bastion Portfolios?

52W Return+43%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+17%9

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+13%8

Rev CAGR (5y)+13%8

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+38%9

EPS Growth Y+3+72%10

Quality

Margins

EBIT Margin2%2

Net Income Margin2%2

Free Cash Flow Margin9%6

Debt

Net Debt/EBITDA-2.610

Efficiency

ROE2%2

ROA2%3

Earnings Stability22

GEAR+WEAK31

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)2641

P/E Ratio (Forward 3y)801

P/BV5.33

EV Multiples

EV/EBITDA Fwd301

EV/EBIT Fwd2841

Yield

Free Cash Flow Yield2.0%4

Dividend Yieldna–

Momentum

Short term

1 month return-1%7

3 month return+58%10

YTD return+35%9

Mid term

Price vs 52wHigh86%7

1 year return+52%9

Long term

3 year return+28%4

5 year return-25%2

Risk Shield

Price Risk

Beta0.76

Volatility46%3

Free Cash Flow

Free Cash Flow Margin9%6

Free Cash Flow Yield2.0%4

Quality

ROCE2%2

Earnings Stability22

Net Debt/EBITDA-2.610

02Growth

Is it actually growing, and how fast?

ATRCAtriCure

Revenue FY25$535M

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+38%9

EPS growth, FY28E+72%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 38%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 17%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return+58%10

YTD return+35%9

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+52%9

3-year return+28%4

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 52% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-1%), over three months (+58%) and so far this year (+35%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+28% over three years and -25% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on AtriCure, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ATRCAtriCure

Revenue FY25$535M

GROWTH RATING↗

STRONG80 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+13%8

Revenue, next 5Y, CAGR+13%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+38%9

EPS growth, FY28E+72%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 80% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 13%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 13%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 38%/yr vs revenue 13%/yr), so margins should widen.

WATCH

Revenue grew 17%/yr over the last 3 years; forecasts see it cooling to 13%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-1%7

3-month return+58%10

YTD return+35%9

MID & LONG-TERM▾SCORE

% of 52-week high86%7

1-year return+52%9

3-year return+28%4

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 52% over the past year, but 14% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (-1%), over three months (+58%) and so far this year (+35%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+28% over three years and -25% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on AtriCure, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community